Market News
Stay updated with the latest market trends, earnings, and economic indicators.

Neutral Indegene; target of Rs 552: Motilal Oswal
Motilal Oswal recommended Neutral rating on Indegene with a target price of Rs 552 in its research report dated May 02, 2026.

Buy Niva Bupa Health Insurance; target of Rs 100: Motilal Oswal
Motilal Oswal recommended is bullish on Niva Bupa Health Insurance recommended buy rating on the stock with a target price of Rs 100 in its research report dated Jun 19, 2026.

SBI MF, Nippon India MF buy Rs 272 crore worth Pine Labs shares; ICICI Pru MF acquire 1.5% stake in Indoco Remedies
SBI Mutual Fund through SBI Midcap Fund held 5.24 percent stake in Pine Labs, the point of sale and payment systems provider, as of March 2026.

Buy Five Star Business Finance; target of Rs 600: Motilal Oswal
Motilal Oswal recommended is bullish on Five Star Business Finance recommended buy rating on the stock with a target price of Rs 600 in its research report dated Jun 22, 2026.

Buy Laurus Labs; target of Rs 1370: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs has recommended buy rating on the stock with a target price of Rs 1370 in its research report dated April 30, 2026.

Neutral Lupin; target of Rs 2520: Motilal Oswal
Motilal Oswal recommended Neutral rating on Lupin with a target price of Rs 2520 in its research report dated May 10, 2026.

Buy Star Health; target of Rs 700: Motilal Oswal
Motilal Oswal is bullish on Star Health recommended buy rating on the stock with a target price of Rs 700 in its research report dated Jun 25, 2026.

Buy Ajanta Pharma; target of Rs 3400: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 3400 in its research report dated May 05, 2026.

Buy Laurus Labs; target of Rs 1280: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 1280 in its research report dated February 25, 2026.

Max Healthcare shares fall up to 7% as Q4 results miss estimates
Analysts at domestic brokerage Motilal Oswal Financial Services said the earnings miss was due to a higher tax rate .

Neutral Blue Star; target of Rs 1920: Motilal Oswal
Motilal Oswal recommended Neutral rating on Blue Star with a target price of Rs 1920 in its research report dated May 07, 2026.

Neutral ALKEM Laboratories; target of Rs 5525: Motilal Oswal
Motilal Oswal recommended Neutral rating on ALKEM Laboratories with a target price of Rs 5525 in its research report dated February 14, 2026.